Xilio Therapeutics Inc.

NASDAQ: XLO · Real-Time Price · USD
0.70
-0.00 (-0.38%)
At close: Aug 15, 2025, 3:59 PM
0.70
-0.74%
After-hours: Aug 15, 2025, 06:54 PM EDT

Xilio Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
2.93M 1.72M 2.26M 2.36M n/a 2.9M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a 449K 460K 492K 499K 489K 473K 445K 440K 394K 382K 373K 350K
Gross Profit
2.93M 1.72M 2.26M 2.36M n/a 2.45M -460K -492K -499K -489K -473K -445K -440K -394K -382K -373K -350K
Operating Income
-13.85M -13.63M -14.76M -14.7M -17.49M -18.13M -17.36M -20.12M -23.53M -23.17M -20.21M -24.55M -21.22M -19.56M -15.96M -23.01M -16.52M
Interest Income
n/a n/a n/a n/a n/a 100K n/a 200.00 n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-13.27M -13.09M -14.02M -13.93M -17.2M -17.66M -16.75M -19.36M -22.65M -22.47M -19.79M -24.61M -21.35M -19.7M -16.25M -23.18M -16.67M
Net Income
-13.27M -13.09M -14.02M -13.93M -17.2M -17.66M -16.75M -19.36M -21.27M -21.77M -19.37M -24.61M -21.48M -19.7M -16.25M -23.18M -16.67M
Selling & General & Admin
8.52M 6.52M 6.31M 5.82M 6.14M 5.95M 6.31M 6.9M 7.39M 8.17M 7.17M 8.31M 6.3M 8.2M 5.49M 5.26M 4.9M
Research & Development
8.27M 8.84M 10.76M 11.22M 10.4M 11.74M 11.05M 13.22M 16.13M 15M 13.04M 16.25M 14.92M 11.35M 10.47M 17.75M 11.62M
Other Expenses
n/a n/a -41K 30K 948K n/a 613K 761K 880K 701K 416K -61K -129K -145K -290K -174K -147K
Operating Expenses
16.78M 15.35M 17.02M 17.06M 17.49M 17.68M 17.36M 20.12M 23.53M 23.17M 20.21M 24.55M 21.22M 19.56M 15.96M 23.01M 16.52M
Interest Expense
n/a n/a n/a n/a n/a 100K 200K 200K n/a n/a n/a n/a 129K n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a 5.94M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
16.78M 15.35M 17.02M 17.06M 17.49M 18.13M 17.36M 20.12M 23.53M 23.17M 20.21M 24.55M 21.22M 19.56M 15.96M 23.01M 16.52M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a -1.38M -701K -416K n/a 129K n/a n/a n/a n/a
Shares Outstanding (Basic)
74.7M 64.68M 63.47M 57.76M 27.91M 27.56M 27.52M 27.47M 27.43M 27.42M 27.4M 27.38M 27.37M 20.06M 26.67M 26.67M 26.67M
Shares Outstanding (Diluted)
74.7M 64.68M 63.47M 57.76M 27.91M 27.56M 27.52M 27.47M 27.43M 27.42M 27.4M 27.38M 27.37M 20.06M 26.67M 26.67M 26.67M
EPS (Basic)
-0.18 -0.2 -0.22 -0.24 -0.62 -0.64 -0.61 -0.7 -0.78 -0.79 -0.71 -0.9 -0.78 -0.98 -0.61 -0.87 -0.63
EPS (Diluted)
-0.18 -0.2 -0.22 -0.24 -0.62 -0.64 -0.61 -0.7 -0.78 -0.79 -0.71 -0.9 -0.78 -0.98 -0.61 -0.87 -0.63
EBITDA
-13.35M -13.25M -14.42M -14.23M -16.1M -17.11M -16.9M -19.62M -23.03M -22.68M -19.73M -24.11M -20.78M -19.16M -15.58M -22.63M -16.17M
EBIT
-13.85M -13.63M -14.8M -14.67M -16.54M -17.55M -17.36M -20.12M -23.53M -23.17M -20.21M -24.55M -21.22M -19.56M -15.96M -23.01M -16.52M
Depreciation & Amortization
497K 375K 381K 445K 443K 449K 460K 492K 499K 489K 473K 445K 440K 394K 382K 373K 350K